Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Recruiting Phase 2 Interventional

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

NCT05237505
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
Interventions
bi-level positive pressure non invasive ventilation, Oxygen gas
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 5:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

SPIROMICS Study of Early COPD Progression (SOURCE)

NCT05033990
View directory record Official record
Conditions
COPD, Early-Onset
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
30 Years to 55 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 5:57 AM EDT
Terminated Not applicable Interventional

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

NCT05569005
View directory record Official record
Conditions
COPD, Smoking, Tobacco Use
Interventions
THS use, Cigarette, Smoking Abstinence
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
35 Years to 65 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
81
States / cities
Brandon, Florida • Cape Coral, Florida • Clearwater, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Not applicable Interventional Results available

RESP-FIT: Technology-Enhanced Self-Management in COPD

NCT03652662
View directory record Official record
Conditions
COPD
Interventions
RESP-FIT, RESP-FIT Comparator
Device · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Torrance, California • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Not applicable Interventional

Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients

NCT01596023
View directory record Official record
Conditions
Chronic Obstructive Lung Disease
Interventions
Breathe NIOV Ventilator
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

NCT01627327
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
11
States / cities
Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 29, 2026, 5:57 AM EDT
Withdrawn No phase listed Observational

Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD

NCT05661435
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
RESP Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 29, 2026, 5:57 AM EDT
Completed No phase listed Observational

Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum

NCT01096173
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
35 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

NCT03311373
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Regimen A, Regimen B, Regimen C, Regimen D
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 29, 2026, 5:57 AM EDT
Terminated Phase 1 Interventional

Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI

NCT05433961
View directory record Official record
Conditions
COPD
Interventions
MagniXene Hyperpolarized Xenon MRI
Drug
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

NCT05161156
View directory record Official record
Conditions
COPD
Interventions
Test Product (tiotropium bromide inhalation powder), 18 mcg of Spiriva (Reference Product), Placebo
Combination Product
Lead sponsor
Phargentis SA
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 29, 2026, 5:57 AM EDT
Terminated Not applicable Interventional

Evaluating Genes in Sputum to Measure Drug Response in COPD

NCT00233051
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Salmeterol or Salmeterol/Fluticasone
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 29, 2026, 5:57 AM EDT
Recruiting No phase listed Observational

University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2

NCT07482475
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Cancer Lung Screening, Smoking Cigarette
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 29, 2026, 5:57 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07759245
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Brenipatide, Placebo, Standard of Care
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Newport Beach, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 5:57 AM EDT
Recruiting Not applicable Interventional

Supporting Evidence-based Responses to Emotional Needs in Emphysema

NCT06600126
View directory record Official record
Conditions
COPD
Interventions
Coping Skills Training, COPD Education
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 29, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00669617
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 29, 2026, 5:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Web-based, Interactive Professional Education for Chronic Obstructive Pulmonary Disease

NCT01377675
View directory record Official record
Conditions
Education of Primary Care Clinicians
Interventions
Education
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 29, 2026, 5:57 AM EDT
Not listed Not applicable Interventional

VISN 23 Chronic Obstructive Pulmonary Disease (COPD) Case Management Using Home Telehealth Equipment

NCT00916799
View directory record Official record
Conditions
COPD
Interventions
Use of Telehealth equipment (Viterian V-100)
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 29, 2026, 5:57 AM EDT
Enrolling by invitation Not applicable Interventional

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

NCT05443321
View directory record Official record
Conditions
Infections, Heart Failure, COPD Exacerbation, Asthma, Gastrointestinal Diseases, Cardiac Event, Arrythmia, Renal Failure, Renal Disease, Rheumatic Diseases, Urologic Diseases, Neurologic Disorder, Hematologic Diseases, Oncology Problem, Shock, Critical Illness
Interventions
Health Information Exchange (HIE) platform
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 29, 2026, 5:57 AM EDT